L1 ANSWER 1 OF 1 CAPLUS COPYRIGHT 2005 ACS on STN
AN 1999:134367 CAPLUS Full-text
DN 130:247044
TI Phenoxypyridines and pharmaceutical compositions containing them
IN Ota, Tomoki; Nakanishi, Misa; Aibe, Izumi; Taguchi, Minoru; Tomisawa, Kazuyuki
PA Taisho Pharmaceutical Co., Ltd., Japan
SO Jpn. Kokai Tokkyo Koho, 8 pp.
CODEN: JKXXAF
DT Patent
LA Japanese
FAN.CNT 1

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI JP 11049752	A2	19990223	JP 1997-210838	19970805 <--
PRAI JP 1997-210838		19970805		

OS MARPAT 130:247044
GI



I

AB Phenoxypyridines I (X = NO2, NHR4; R4 = H, lower alkyl, carbamoyl, thiocarbamoyl, lower alkoxycarbonyl; R1 = H, NO2, lower alkyl; R2 = H, lower alkyl, lower alkoxy, halo, cyano, lower perfluoroalkyl) or their pharmacol. acceptable salts are useful for pharmaceutical compns. The compns. are useful for inhibition of Na+/Ca2+ exchange systems, treatment or prevention of ischemic heart, brain, or kidney diseases, or cell-protecting agents in thrombolytic therapy or surgery for blood vessel formation, coronary artery bypass, or organ transplantation. The Na+/Ca2+ exchange activity of canine myocardial membrane vesicles was decreased to 48% of controls in the presence of 1 μM 2-[4-(3- fluorobenzyloxy)phenoxy]-5-nitropyridine.